Lymphoma, Mantle-Cell < Lymphoma, Non-Hodgkin < Lymphoma, T-Cell

Facettes :

List of bibliographic references indexed by Lymphoma, Non-Hodgkin

Number of relevant bibliographic references: 65.
[0-20] [0 - 20][0 - 50][20-40]

Ident.	Authors (with country if any)	Title
000D84 (2012)		Feasibility of bremsstrahlung dosimetry for direct dose estimation in patients undergoing treatment with 90Y-ibritumomab tiuxetan.
000F35 (2012)		Concepts, consequences, and implications of theranosis.
001944 (2010)		Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclides.
001948 (2010)		Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma.
001C09 (2009)		The role of dosimetry in the high activity 90Y-ibritumomab tiuxetan regimens: two cases of abnormal biodistribution.
001D82 (2009)		MIRD dose estimate report No. 20: radiation absorbed-dose estimates for 111In- and 90Y-ibritumomab tiuxetan.
002483 (2008)		90Y-ibritumomab therapy in refractory non-Hodgkin's lymphoma: observations from 111In-ibritumomab pretreatment imaging.
002589 (2007)		Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma.
002804 (2007)		Characteristics of dimeric (bis) bidentate selective high affinity ligands as HLA-DR10 beta antibody mimics targeting non-Hodgkin's lymphoma.
002828 (2007)		A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.
002B77 (2005)		The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma.
002B78 (2005)		The role of imaging with (111)In-ibritumomab tiuxetan in the ibritumomab tiuxetan (zevalin) regimen: results from a Zevalin Imaging Registry.
002C07 (2005)		Splenic volume change and nodal tumor response in non-Hodgkin's lymphoma patients after radioimmunotherapy using radiolabeled Lym-1 antibody.
002D52 (2005)		Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody.
003056 (2004)		Imaging and dosing in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
003232 (2003)		Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
003233 (2003)		Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
003238 (2003)		Prognostic value of FDG-PET in malignant lymphoma.
003317 (2003)		Impact of interpatient pharmacokinetic variability on design considerations for therapy with radiolabeled MAbs.
003371 (2003)		Comparative physical and pharmacologic characteristics of iodine-131 and yttrium-90: implications for radioimmunotherapy for patients with non-Hodgkin's lymphoma.
003430 (2002)		Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=IndiumV2/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/MedMesh.i -k "Lymphoma, Non-Hodgkin" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/MedMesh.i  \
                -Sk "Lymphoma, Non-Hodgkin" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=   *** parameter Area/wikiCode missing *** 
   |area=    IndiumV2
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    MedMesh.i
   |clé=    Lymphoma, Non-Hodgkin
}}

---

This area was generated with Dilib version V0.5.76. Data generation: Tue May 20 07:24:43 2014. Site generation: Thu Mar 7 11:12:53 2024